April 18, 2026

Kratom & Research: Current Studies, Alkaloids and the State of Science

by amama in plants

This article is Part 6 of 7 in our Kratom series and serves as the scientific anchor. For the overview, see the complete Kratom guide.

TL;DR

Mitragynine is the main alkaloid (~66%) and a partial μ-opioid receptor agonist with GPCR bias — a signaling profile that differs from classical opioids.
The 2021 WHO review recommended no international scheduling of kratom.
Grundmann (2017) provided the largest user data collection to date with 8,049 respondents; Singh et al. (2014) documented long-term use in Malaysia.
7-Hydroxymitragynine is a minor alkaloid, but significantly more potent at the MOR than mitragynine.
Knowledge gaps: long-term clinical studies, optimal dose ranges, interaction profiles.
Publication numbers have been rising steadily since 2017 — kratom is an active research field.

Botanical name	Mitragyna speciosa (Korthals, 1839)
Plant family	Rubiaceae (coffee family)
Origin	Southeast Asia — Thailand, Malaysia, Indonesia (Borneo)
Primary alkaloids	Mitragynine (~66 %), 7-Hydroxymitragynine (~2 %)
Available forms	Powder, capsules, liquid extract
Legal status (DE)	Legal — not listed in BtMG or NpSG

The Main Alkaloids of Kratom

The leaf of Mitragyna speciosa contains over 40 identified alkaloids. Their composition determines the pharmacological profile of any given preparation. A detailed profile page on mitragynine can be found here.

Mitragynine

Primary alkaloid, about 66% of the alkaloid fraction in the dried leaf. CAS number 4098-40-2, PubChem CID 3034396. In vitro and animal model studies characterize mitragynine as a partial agonist at the μ-opioid receptor (MOR) with GPCR bias — meaning it activates downstream signaling pathways differently from classical opioids (e.g., preferential G-protein activation over β-arrestin recruitment). This bias is discussed as a possible reason for a differing side effect profile.

Additionally, mitragynine shows activity at α2-adrenergic receptors and serotonin receptors (5-HT2A, 5-HT2C) in in vitro assays. Important caveat: these findings stem predominantly from in vitro and animal studies. Human clinical data are limited.

7-Hydroxymitragynine (7-OH-M)

Minor alkaloid, approximately 2% of total alkaloids, but significantly more potent at the MOR than mitragynine. 7-OH-M is also formed via metabolic conversion from mitragynine in vivo (CYP3A4-mediated). The ratio of mitragynine to 7-OH-M varies between preparations and extracts and may be a key determinant of the effect profile.

Speciociliatine, Speciogynine, Paynantheine

Secondary alkaloids with less well-studied pharmacology. Speciociliatine may act as a weak partial opioid agonist. Paynantheine and speciogynine contribute to the complex alkaloid fingerprint that distinguishes kratom from isolated mitragynine — a distinction often underestimated in pharmacological assessment.

Key Studies

Grundmann 2017 — The Largest User Survey

Grundmann, O. (2017). Patterns of kratom use and health impact in the US — results from an online survey. Drug and Alcohol Dependence, 176, 63–70. DOI: 10.1016/j.drugalcdep.2017.01.011

Online survey of 8,049 kratom users in the US — the most extensive self-reported data collection to date. Key findings:

Majority reported use for pain management, mood support, and accompanying opioid withdrawal.
Most respondents reported mild or no side effects.
Physical dependence was reported by a minority of long-term, high-dose users.

Limitation: self-reported online survey, not a clinical study design — but nevertheless the most valuable snapshot of real-world usage patterns.

Singh et al. 2014 — Traditional Users in Malaysia

Singh, D., Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 139, 132–137. DOI: 10.1016/j.drugalcdep.2014.03.017

Study of traditional users in Malaysia — relevant because these individuals consume kratom in some cases for decades as a cultural practice. The authors document that dependence and withdrawal symptoms can occur with chronic high-dose use (daily, over years), though the withdrawal symptoms were generally less pronounced than with classical opioids.

Vicknasingam et al. 2010 — Ketum as Harm Reduction

Vicknasingam, B., Narayanan, S., Beng, G. T., & Mansor, S. M. (2010). The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia. Journal of Ethnopharmacology, 127(2), 395–399. DOI: 10.1016/j.jep.2009.10.004

Ethnographic documentation of the traditional use of kratom tea (ketum) to manage opioid withdrawal symptoms in northern Malaysia. Important for understanding the cultural and harm-reduction context in which much of the evidence has emerged.

Prozialeck et al. 2012 — Pharmacological Review

Prozialeck, W. C., Jivan, J. K., & Bhatt, D. K. (2012). Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. Journal of the American Osteopathic Association, 112(12), 792–799.

Foundational pharmacological review article covering alkaloid mechanisms, traditional use, and open clinical questions. Frequently cited as an entry-level reference.

Kruegel & Grundmann 2018 — Modern Receptor Characterization

Kruegel, A. C., & Grundmann, O. (2018). The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology, 134 (Part A), 108–120. DOI: 10.1016/j.neuropharm.2017.08.026

Detailed analysis of receptor pharmacology, including discussion of GPCR bias and its clinical implications.

The 2021 WHO Review: A Significant Outcome

The WHO Expert Committee on Drug Dependence (ECDD) conducted a pre-review on kratom at its 44th meeting in 2021. The outcome:

The committee recommended not to proceed to a critical review and not to schedule kratom internationally.

This is a significant science-policy outcome: kratom remains unregulated at the UN level, and the German legal situation (not listed under the BtMG or NpSG) is consistent with this international position. More on the legal context in our article on the legal situation in Germany.

What this does not mean: It is not a recommendation or endorsement. The WHO explicitly noted that more research is needed — particularly on dependence potential, vulnerable populations, and clinical safety.

Current Research Landscape

The number of peer-reviewed publications on kratom has increased markedly between 2017 and 2025. Key research groups:

University of Florida (Dr. Oliver Grundmann, Dr. Christopher McCurdy): ongoing pharmacological and clinical surveys.
Johns Hopkins University (Dr. Albert Garcia-Romeu and colleagues): publications on usage patterns and dependence.
University of Rochester, Columbia University: mechanistic work on GPCR bias and structure-activity relationships.
Universiti Sains Malaysia (Dr. Darshan Singh): ethnopharmacological and long-term use studies.

What We Don't Yet Know

An honest overview of the evidence gaps:

Area	Status
Long-term clinical studies in humans	largely missing
Optimal dose ranges for potential applications	not established
Interactions with other substances (CYP interactions)	limited investigation
Hepatotoxicity	case reports exist, causality contested, rare
Safety in pregnancy/lactation	not known, use is explicitly not recommended
Pharmacokinetics in humans	partially characterized, incomplete

The research situation on kratom is active, but far from what could be called complete. This is the honest state of affairs.

Back to the Guide

Sources (complete)

Korthals, P. W. (1839). Observationes de Nauclearum Indicarum. First description of Mitragyna speciosa, Dutch East Indies.
Prozialeck, W. C., Jivan, J. K., & Bhatt, D. K. (2012). Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. Journal of the American Osteopathic Association, 112(12), 792–799.
Hassan, Z., Muzaimi, M., Navaratnam, V., et al. (2013). From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neuroscience & Biobehavioral Reviews, 37(2), 138–151. DOI: 10.1016/j.neubiorev.2012.11.012
Singh, D., Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 139, 132–137. DOI: 10.1016/j.drugalcdep.2014.03.017
Vicknasingam, B., Narayanan, S., Beng, G. T., & Mansor, S. M. (2010). The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia. Journal of Ethnopharmacology, 127(2), 395–399. DOI: 10.1016/j.jep.2009.10.004
Grundmann, O. (2017). Patterns of kratom use and health impact in the US — results from an online survey. Drug and Alcohol Dependence, 176, 63–70. DOI: 10.1016/j.drugalcdep.2017.01.011
Kruegel, A. C., & Grundmann, O. (2018). The medicinal chemistry and neuropharmacology of kratom. Neuropharmacology, 134(A), 108–120. DOI: 10.1016/j.neuropharm.2017.08.026
Kruegel, A. C., Uprety, R., Grinnell, S. G., et al. (2019). 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Central Science, 5(6), 992–1001. DOI: 10.1021/acscentsci.9b00141
WHO Expert Committee on Drug Dependence (2021). 44th Meeting Report — Pre-Review of Kratom (Mitragyna speciosa), Mitragynine and 7-Hydroxymitragynine. Geneva: World Health Organization.
PubChem CID 3034396 (Mitragynine) — National Center for Biotechnology Information, U.S. National Library of Medicine.
Veltri, C., & Grundmann, O. (2019). Current perspectives on the impact of Kratom use. Substance Abuse and Rehabilitation, 10, 23–31. DOI: 10.2147/SAR.S164261

Last updated: 2025. This article is for educational purposes only and does not constitute medical advice. Kratom research is active and evolving — individual statements may be refined or revised by new studies. For health-related questions, please consult qualified medical professionals.

Muscimol 2D structure of Muscimol (C4H6N2O2) — source: PubChem CID 4266 Chemistry CID: 4266 · PubChem Formula: C4H6N2O2 Molecular weight: 114.1 g/mol IUPAC: 5-(aminomethyl)-1,2-oxazol-3-one CAS: 2763-96-4 Family & pharmacology Family: Isoxazole (not an indole alkaloid) Pharmacological class: GABA-A receptor full agonist — binds selectively and potently at the GABA-binding site (orthosteric site) of GABA-A receptors, producing sedative, hypnotic, anxiolytic, and at higher doses dissociative/psychedelic effects. Unlike benzodiazepines (which act allosterically), muscimol is a direct agonist and therefore active even in the absence of endogenous GABA. It does not act on serotonergic (5-HT₂A) or dopaminergic pathways. Natural source: Muscimol is the primary psychoactive constituent of Amanita muscaria (fly agaric) and related Amanita species including A. pantherina and A. regalis. It is formed in vivo and during drying/cooking by decarboxylation of ibotenic acid, a structural precursor also present in fresh fruiting bodies. The ratio of ibotenic acid to muscimol is highly variable and depends on drying temperature and time. Historical context Muscimol was first isolated in 1964 by Swiss chemist Conrad Hans Eugster and colleagues at the University of Zurich, who also elucidated its structure and confirmed its GABAergic mechanism. Interest in Amanita muscaria as a psychoactive agent long predates isolation: ethnomycologist R. Gordon Wasson proposed in 1968 (Soma: Divine Mushroom of Immortality) that fly agaric was the identity of Soma, the sacred beverage described in the Rigveda — a hypothesis that remains debated among ethnobotanists and classicists. Siberian and Eurasian accounts of fly agaric use — particularly among Koryak, Chukchi, and Evenki reindeer herders — were documented by European travellers from the 18th century onward. The anthropologist Jochen Gartz and others have argued that the reindeer–Amanita relationship (reindeer actively seeking fly agaric) has contributed to shamanic iconography including the Santa Claus myth. Traditional use Siberian shamanic ritual: fly agaric dried and consumed by shamans to induce visionary states; urine recycling (muscimol is excreted largely unchanged) was documented in several ethnohistorical sources Reindeer herding communities in northeastern Siberia consumed fly agaric to reduce fatigue and pain on long journeys Not documented in significant traditional use contexts in Central or Western Europe, despite widespread occurrence of A. muscaria Modern research context Contemporary research interest in muscimol centres on its GABA-A agonism as a tool compound to map receptor subunit specificity, and on potential therapeutic applications in anxiety and epilepsy. Muscimol's selectivity profile differs from benzodiazepines and barbiturates, and unlike many GABA-A modulators it does not require a specific subunit combination, making it a useful research probe. Muscimol shows anticonvulsant effects in animal models and has been investigated for neuroprotective properties in ischemia models. It is important to note that muscimol has no serotonergic activity — its experiential profile (sedation, dreamlike states, body effects) differs substantially from classical psychedelics (psilocybin, LSD). Clinical research in humans remains limited; most data derive from animal pharmacology. Safety Muscimol is potent at low doses (effective dose range reported in the single-digit milligram range in experienced users). Fresh Amanita muscaria fruiting bodies contain predominantly ibotenic acid, which must be converted to muscimol by decarboxylation (typically via controlled drying at 50–70 °C). Ibotenic acid is a neuroexcitatory NMDA receptor agonist that contributes to nausea and dysphoria. Improperly prepared material therefore carries higher risk than preparations where decarboxylation is complete. Dose–response is steep and highly variable between specimens. Adverse effects include nausea, vomiting, excessive salivation, confusion, and ataxia. There is no specific antidote; supportive care is standard. Combining muscimol with alcohol or other CNS depressants significantly increases the risk of respiratory depression. Not appropriate for unsupervised use. Legal status in Germany As of 2026, muscimol is not scheduled in the German Narcotics Act (BtMG, Anlagen I–III) and is not listed in the New Psychoactive Substances Act (NpSG). Amanita muscaria mushrooms and muscimol-containing preparations are legal to possess, purchase, and sell in Germany. There is no medicinal-use restriction comparable to that affecting ibogaine or psilocybin. Amanita muscaria extracts and dried fruiting bodies are openly traded as botanical specimens. Related content Plant Extracts at amama Ibogaine — Compound Profile Mitragynine — Compound Profile

Learn more

May 14, 2026

Yopo: The Sacred Snuff of the Orinoco Tribes

This article is part of our Rapé Guide. TL;DR Yopo is a ritual snuff made from the seeds of Anadenanthera peregrina, used for centuries by indigenous tribes of the Orinoco Basin. Plant: Anadenanthera peregrina (Mimosaceae) – not to be confused with Rapé Tradition: Piaroa, Yanomami, Cuiva and Wayuu use Yopo in healing and initiation rites Active compounds: Primarily bufotenin (5-OH-DMT) and DMT in the seeds – no nicotine as in Rapé Legal status DE: Anadenanthera seeds themselves are not listed; bufotenin and DMT are BtMG Schedule I – use is illegal amama does not offer Yopo – this article serves exclusively ethnobotanical education What is Yopo? Yopo refers to the dried and roasted seeds of the leguminous plant Anadenanthera peregrina, and less commonly Anadenanthera colubrina (Cébil), both members of the family Mimosaceae. The trees reach heights of up to 20 metres and grow preferentially in the savannahs and transitional zones between the Orinoco Basin and the Amazon – in Venezuela, Colombia and the northern regions of Brazil. The ethnobotanical history of Yopo extends back at least 4,000 years. Archaeological finds of snuffing implements and prepared seeds in Chilean and Argentinian burial sites demonstrate that the use of this plant is far older than the Aztec or Inca civilisations. In the lowland regions of northern South America, Yopo remains a living part of indigenous ceremonial practice to this day. The main groups that traditionally use Yopo include the Piaroa and Cuiva in Venezuela and the Yanomami in the Venezuela–Brazil border region. The plant is also known among the Wayuu of the Guajira Peninsula. Each of these groups has its own preparation methods, ceremonial contexts and names for the substance – "Yopo" itself is a loanword from Piaroa. The first European accounts come from Alexander von Humboldt, who described its use in 1801 during his South American journey on the Orinoco and reported on the intense effects it had on shamans. The botanist Richard Spruce classified the plant more precisely in 1851 and offered the first chemical hypotheses. The complete isolation of the primary active compound bufotenin was not achieved until the 20th century. Important: Yopo and Rapé are fundamentally different substances. Rapé is based on Nicotiana rustica and contains nicotine as its primary active compound. Yopo contains tryptamines (bufotenin, DMT). Their pharmacology, tradition, effects and legal status differ fundamentally. Active Compounds and Chemistry The psychoactive effects of Yopo stem from a specific group of indole alkaloids concentrated in the seeds of Anadenanthera peregrina: Bufotenin (5-Hydroxy-DMT, 5-OH-DMT): The quantitatively dominant active compound. Depending on origin and preparation method, concentrations of 3–5% of the dry weight of the seeds are reported. Bufotenin is a potent agonist at the 5-HT2A serotonin receptor and is considered the primary agent responsible for visionary effects. DMT (N,N-Dimethyltryptamine): Present in the seeds in trace amounts, more concentrated in the tree's bark. Presumed to amplify the overall effect of the alkaloid profile. 5-MeO-DMT: Detected in smaller concentrations – pharmacologically highly potent, contributing to the overall profile. Beta-carbolines (MAO inhibitors): Present in Anadenanthera only in small quantities, yet relevant: they inhibit monoamine oxidases (MAO-A), which normally break down tryptamines rapidly in the body. This inhibition can prolong and intensify the oral and nasal bioavailability of the active alkaloids – particularly relevant in combination with ayahuasca-like preparations. Comparison to Rapé: Nicotiana rustica contains nicotine as its primary active compound, acting at the nicotinic acetylcholine receptor (nAChR) – a classic stimulant profile with grounding, focusing effects. Yopo's tryptamines, by contrast, are 5-HT2A agonists with a distinctly visionary-psychedelic effect profile. These are pharmacologically entirely different substance classes. Tradition of Use In indigenous practice, Yopo is not a recreational substance but a ceremonial tool – embedded within cosmological worldviews in which shamans (healers or Wisiratu among the Piaroa) act as intermediaries between the human and spiritual worlds. Preparation is elaborate: ripe seeds are roasted, ground in a mortar and frequently mixed with lime (from shell or snail lime) or the ash of certain pods. The lime raises the pH of the mixture, which facilitates the release of the free base forms of the tryptamines from their salts and improves nasal absorption – a principle also known from coca leaves used with lime. Inhalation is performed through Y-shaped bone tubes (often made from bird bones), which are formally distinct from the Tepi and Kuripe pipes of Rapé, although the basic principle – blowing powder into the nose – is similar. In some tribes, a shaman blows the powder into both nostrils of a patient or initiate. Yopo ceremonies frequently take place in the context of initiation rites, healing rituals and preparation for hunting. Among the Yanomami, the use of yakoana (their term for a related snuff product derived from Virola root bark) is strongly associated with shamanic status – similar structures are found among Yopo users. The experience is regarded as making contact with Hekura (spirit beings), not as intoxication. A combination with ayahuasca (MAO inhibition through Banisteriopsis caapi) has been documented in certain contexts and considerably intensifies the effects. Yopo is not an everyday substance. Unlike tobacco Rapé, which is used regularly in many tribes, Yopo is an exceptional experience tied to specific ceremonial conditions. Yopo vs. Rapé — The Differences Aspect Yopo Rapé Primary plant Anadenanthera peregrina Nicotiana rustica Family Mimosaceae Solanaceae Primary active compound Bufotenin / DMT Nicotine Pharmacology 5-HT2A agonist (tryptamine) nAChR agonist (stimulant) Effect profile Visionary, psychedelic Grounding, focusing, purifying Acute duration 30–60 minutes 5–20 minutes Tradition Orinoco Basin (VE/CO/BR) Western Amazon Basin (Acre, Peru) Application tool Y-shaped bone tube Tepi (administered by another) / Kuripe (self-administered) Ceremonial role Exceptional ritual, shamanism Part of daily life and ceremony Legal status DE Seeds legal / use illegal Fully legal → For a deeper exploration of Rapé: Rapé Guide and Rapé Effects Legal Status in Germany and the EU A precise distinction is required here that is absent from many sources: Anadenanthera seeds as botanical material are not listed in Germany's Narcotics Act (BtMG) or the New Psychoactive Substances Act (NpSG). The purchase and possession of seeds as an ornamental plant or botanical collectible is legal under current legislation. Bufotenin (5-OH-DMT) and DMT, however, are BtMG Schedule I in Germany – non-tradeable narcotics with no medical authorisation. This means: any action aimed at the extraction, preparation or application of the psychoactive compounds from the seeds is subject to criminal prosecution. Practical consequence: An Anadenanthera seed on a windowsill is a plant. That same seed, roasted, ground and prepared with lime for nasal inhalation, constitutes a BtMG-relevant action. The boundary lies in the discernible intent of use. EU Overview: Netherlands: Anadenanthera added to Schedule II of the Opium Act (2017) – more restrictive than Germany Spain: No explicit listing of the plant, but tryptamines are controlled France: General prohibition of tryptamines – restrictive interpretation encompasses Yopo use Austria: BtMG-analogous to Germany amama does not offer Yopo. This article serves exclusively ethnobotanical and pharmacological education. What Users Report — Anecdotal Perspectives The following themes are based on publicly available experience reports on [Erowid](https://www.erowid.org/), Reddit (r/Ayahuasca, r/PsychonautRoundtable) and ethnographic field reports. These are self-reported, anecdotal observations – not clinical data. They are presented here for informational purposes only. Common Themes in Experience Reports Rapid onset of effects: Due to nasal absorption, effects begin significantly faster than with oral ingestion – reports describe onset within seconds to a few minutes Intense visionary component: Geometric patterns, colour experiences and what users describe as "encounters with spirit beings" or "entities" are recurring themes – structurally similar to DMT experiences, but with a character of their own Pronounced "body load": Nausea, dizziness, sweating and physical discomfort are described very frequently and are considered a "normal" part of the experience within the community Shorter overall duration than ayahuasca: The acute phase is reported as 30–60 minutes – compared to 4–6 hours with ayahuasca Difficult to control: Unlike Rapé, the intensity of a Yopo experience can barely be modulated – reports of unexpectedly overwhelming intensity are common Warnings from the Community The experience is consistently rated as significantly more intense than anticipated – first-time users frequently underestimate its potency Cardiovascular reactions (racing heart, elevated blood pressure) are frequently reported – pharmacologically plausible through bufotenin's 5-HT2B activity Combination with MAO inhibitors or SSRIs is strictly discouraged in the community – reports of serotonin syndrome exist Risks and Contraindications From an ethnopharmacological and clinical perspective, the following risks are relevant: Cardiovascular: Bufotenin acts not only at the 5-HT2A receptor but also at 5-HT2B – the latter is associated with cardiac effects (cardiac arrhythmias, acute blood pressure elevation). This represents a serious risk, particularly in individuals with pre-existing heart conditions. MAO inhibitor combination: Ayahuasca combinations, MAO inhibitor medications or harmaline-containing plants can dramatically prolong and intensify the tryptamine effect – with potentially life-threatening consequences. Serotonin syndrome: Combination with SSRIs, SNRIs or other serotonergic substances is contraindicated. Pre-existing mental health conditions: A personal or family history of psychotic disorders (schizophrenia, bipolar disorder) is considered an absolute contraindication for potent psychedelics. Pregnancy and breastfeeding: Absolutely contraindicated. Setting: Deep tryptamine experiences require a safe setting and experienced supervision. Undertaken alone, the experience carries considerable risks – both psychological and physical. Legally: Use is subject to criminal prosecution in Germany. No self-experimentation. Is Yopo Available at amama? No. Since bufotenin and DMT – the primary active compounds in Yopo seeds – are classified as BtMG Schedule I substances in Germany, amama does not sell Yopo in any form: neither as seeds for use, nor as an extract or preparation. This article is part of our educational offering on ethnobotany – similar to our informational articles on Iboga or Peyote. We believe that informed people make better decisions. That is why we contextualise what Yopo is, where it comes from and why it cannot be freely available in Germany. If you are looking for a legal, traditional snuff product rooted in the tribal traditions of the Amazon: Rapé made from Nicotiana rustica is the most closely related sister product – with its own deep tradition, well-documented pharmacology and full legality in Germany. → Rapé Collection at amama → Rapé Guide: Tradition, Effects, Application Related Topics from the amama Universe **Rapé Guide** — the legal sister tradition from the Amazon **Rapé Ceremony** — indigenous tradition of use and ceremonial context **Rapé Effects** — nicotine-based pharmacology in direct comparison to Yopo's tryptamines **Iboga Guide** — another traditional botanical with a pronounced shamanic tradition and complex legal status **Nicotine Substance Profile** — Rapé's primary active compound in pharmacological detail Last updated: May 2026. Pure educational article. No product offering. amama does not sell Yopo.

Learn more

April 28, 2026

Blue Lotus Tea: Preparation, Dosage and Recipes

Nymphaea caerulea (Blue Egyptian Lotus). Plate from 'Flore des Serres et des Jardins de l'Europe', edited by Louis van Houtte, 1851–52. The blue lotus was sacred in ancient Egypt — depicted in temples, tombs, and papyri from the Old Kingdom through to the Greco-Roman period. This is part of our Ultimate Blue Lotus Guide. TL;DR — Blue lotus tea is a water- or milk-based infusion of dried Nymphaea caerulea flowers, traditionally prepared to extract its primary alkaloids, nuciferine and apomorphine. Three reliable preparation methods exist: a classic hot infusion (10–15 minutes at 80–90 °C), an overnight cold infusion for a smoother alkaloid profile, and a milk-based "lotus chai" that may improve fat-soluble compound extraction. Total preparation time ranges from 15 minutes (hot tea) to 8–12 hours (cold brew). A cautious starting dose for new users is 3 g of dried flowers per cup; most ethnobotanical literature and community sources suggest 5–7 g for a casual evening session. Blue lotus should not be combined with alcohol, MAOIs, or prescription sedatives, and is not appropriate during pregnancy or breastfeeding. Key points at a glance: What it is: A botanical infusion made from dried blue lotus (Nymphaea caerulea) flowers, consumed for centuries across various cultures. Three primary methods: Hot tea, cold infusion, and milk-based "lotus chai" — each with a distinct alkaloid-extraction profile and onset curve. Preparation time: 15 minutes (hot) to overnight (cold infusion). Hedged dosage: 3 g for a first session; 5–7 g for typical casual use; above 10 g per session is not recommended without prior familiarity with the plant. Safety first: Contraindicated with MAOIs, prescription sedatives, blood pressure medication, and during pregnancy or breastfeeding. Not suitable before driving. What Is Blue Lotus Tea? Blue lotus tea is an aqueous or milk-based infusion prepared from the dried flowers and petals of Nymphaea caerulea, a water lily native to the Nile basin and parts of South and Southeast Asia. The plant's primary bioactive compounds — the aporphine alkaloids nuciferine and apomorphine — are extracted during steeping and consumed in the resulting liquid. Aporphine alkaloid · Nymphaea caerulea Nuciferine (6aR)-1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline Molecular formula: C19H21NO2 Molecular weight: 295.4 g/mol CAS: 475-83-2 Compound profile: Nuciferine → The use of blue lotus as a prepared beverage has deep historical roots. Ancient Egyptian iconographic evidence, including the famously detailed Nebamun pond garden frescoes (circa 1350 BCE, now housed in the British Museum), depicts lotus flowers alongside cups and vessels in ritual and festive contexts. Textual and archaeological sources also reference lotus combined with fermented wine and milk — suggesting that the Egyptians understood, on some practical level, that liquid extraction was an effective preparation method. In contemporary ethnobotanical practice, blue lotus tea occupies a distinct niche: it is approachable, easy to prepare at home, and allows for meaningful control over dosage in a way that smoking, for example, does not. It is most commonly consumed in the evening for its reported relaxation and mild dream-enhancing qualities. Why Tea? (vs. Smoking, Tincture) Different preparation methods produce meaningfully different experiences, largely due to variation in onset speed, alkaloid bioavailability, and duration. The table below summarises the key differences: Method Onset Duration Best for Hot tea 30–45 min 2–4 hours Evening relaxation, mild effect Cold infusion 1–2 hours 3–5 hours Smoother, deeper relaxation Milk-based ("lotus chai") 30–45 min 2–4 hours Improved alkaloid extraction (fat-soluble) Tincture 15–30 min 2–3 hours Precise dosing, long shelf life Smoking 5–10 min 30–60 min Quick effect, less traditional Tea preparation occupies a practical middle ground. It is slower than smoking and tincture, but more forgiving for newcomers, more aligned with traditional preparation methods, and considerably easier to adjust in terms of quantity and concentration. For anyone approaching blue lotus with a ritual or wellness framework, a carefully prepared cup of tea is typically the most coherent starting point. Recipe 1 — Classic Hot Blue Lotus Tea (DE: Klassischer Heißaufguss) This is the most accessible entry point. Keep the process slow and deliberate — rushing any step tends to produce a noticeably weaker result. You will need: 3–5 g dried Nymphaea caerulea flowers (3 g for a first session) 250 ml filtered water Fine mesh strainer or tea strainer Optional: 1 tsp raw honey, a squeeze of lemon Method: Measure your flowers. Start with 3 g for a first experience; 5 g is appropriate once you understand how your body responds. Whole dried flowers are preferable to pre-ground material — they retain volatile compounds longer. Heat your water to 80–90 °C. This is the single most important technical detail in this recipe. Do not bring the water to a full boil — boiling temperatures (100 °C) are known to degrade heat-sensitive alkaloids, particularly nuciferine. Use a temperature-controlled kettle, or boil water and allow it to rest uncovered for 3–4 minutes before pouring. Steep for 10–15 minutes, covered. Covering the vessel during steeping is essential. Blue lotus contains volatile aromatic compounds that will escape with rising steam if the cup is left open, reducing both the sensory quality and the potency of the final tea. Strain through a fine mesh. Remove all plant material thoroughly. Add honey or lemon if desired. Honey softens the slightly earthy, faintly floral bitterness of the tea. A small squeeze of lemon can brighten the flavour and may marginally improve nuciferine solubility in water. Drink slowly over 10–15 minutes. Effects build gradually over 30–45 minutes. There is no value in rushing. What to expect: Most users report a gentle onset of relaxation, mild mood elevation, and — if consumed 60–90 minutes before bed — increased vividness in dreams. The experience is generally described as subtle rather than overwhelming. Recipe 2 — Cold Infusion (DE: Kaltauszug) The cold infusion method is slower and requires planning ahead, but many experienced users consider it the most refined preparation. Cold water extraction is gentler on heat-sensitive compounds, potentially preserving a broader alkaloid profile. You will need: 5 g dried Nymphaea caerulea flowers 500 ml cold filtered water Glass jar with lid Fine mesh strainer Method: Place 5 g of dried blue lotus flowers into a clean glass jar. Add 500 ml of cold, filtered water. Seal and refrigerate for 8–12 hours — overnight is the practical standard. Strain through a fine mesh strainer, pressing gently on the plant material to extract remaining liquid. Drink at room temperature or warm very gently (keep well below 80 °C to preserve the cold-extraction benefit). Why this works: Nuciferine and apomorphine are moderately sensitive to heat. Cold water extraction proceeds more slowly but avoids thermal degradation, and some ethnobotanical practitioners argue the resulting liquid has a noticeably fuller, more rounded quality. Onset is slower — expect 1–2 hours to initial effect — but the overall arc tends to be longer and smoother than a hot-tea preparation. This method is particularly well-suited to an evening ritual: prepare your infusion in the morning, refrigerate through the day, and consume in the early evening. Recipe 3 — Milk-Based "Lotus Chai" (DE: Milchaufguss) This is the most complex of the three core preparations, and the one most frequently described in ethnobotanical literature as the approach closest to attested ancient practice. Whole milk — or a high-fat plant milk — provides a matrix in which fat-soluble alkaloids can dissolve more readily than in water alone. You will need: 250 ml whole cow's milk, or oat milk with a minimum 3% fat content 4–5 g dried Nymphaea caerulea flowers Optional: 1 cardamom pod, lightly crushed; 1 small cinnamon stick; a pinch of freshly grated nutmeg Raw honey to sweeten Method: Combine the milk and dried blue lotus flowers in a small saucepan. Add any optional spices at this stage. Heat the mixture gently to approximately 80 °C — a low simmer with occasional small bubbles at the edge of the pan. Do not bring to a full boil. Maintain this temperature for 15 minutes, stirring occasionally. Keep the pan covered between stirs. Remove from heat and strain through a fine mesh into a mug or cup. Stir in raw honey to taste while the liquid is still warm. Why this is considered the most effective extraction: Archaeological and textual sources reference lotus prepared in both fermented wine and milk in ancient Egyptian and South Asian contexts. Fat-soluble compounds require a lipid medium for optimal solubility. In practical terms, most experienced users report that a milk-based preparation at equivalent flower quantities produces a noticeably fuller response than a plain hot-water tea. If you are working with a limited quantity of dried material and want reliable results, this is the method to use. Dosage Guidance (Hedged — Personal Experimentation) Dosage with blue lotus tea is not a precise science. The alkaloid content of dried flowers varies depending on growing conditions, harvest timing, storage quality, and preparation method. The figures below reflect the approximate consensus across ethnobotanical literature and community-reported anecdotal practice (including r/BlueLotus, r/herbalism, and Erowid experience reports). They are starting points, not prescriptions. Experience level Recommended starting quantity Method First time 3 g Hot tea Casual evening use 5 g Hot tea or cold infusion Deeper relaxation 7–10 g Milk-based preparation Above 10 g per session Not recommended without substantial prior experience — The most important principle is to start low and evaluate your personal sensitivity before increasing quantity. Blue lotus is not a plant with a notably dangerous dose ceiling in most healthy adults, but the variance in individual response — and the variance in dried material quality — is wide enough that caution on the first occasion is simply sensible practice. When to Drink: Timing and Setting The context in which you consume blue lotus tea shapes the experience considerably: 60–90 minutes before bed is the most commonly recommended timing for those seeking relaxation and sleep support. Avoid combining with alcohol — both produce CNS sedation, and the additive effect is difficult to predict and generally undesirable. Avoid combining with prescription sedatives, MAOIs, or strong sleep medications — see the Safety section below. Plan for 4+ hours before any driving or operating machinery. The sedative component of nuciferine is not compatible with tasks requiring full alertness. Setting matters. Blue lotus tea is best consumed in a quiet, familiar environment. Dim lighting, minimal noise, and no obligations for the next few hours create the conditions in which the plant's subtler qualities are most noticeable. What Users Report: Themes from Community Sources The following is a synthesis of recurring themes from public community discussion — including r/BlueLotus, r/herbalism, and Erowid experience archives — and should be understood as anecdotal, not clinical: Mild euphoria and physical relaxation are the most commonly reported effects, typically beginning 30–45 minutes after a hot-tea preparation and somewhat later with cold infusion. Vivid or more memorable dreams are frequently noted when blue lotus is consumed 60–90 minutes before sleep. This aligns with apomorphine's known activity at dopamine receptors involved in REM modulation. Mood lift is consistently described as "gentle" and "warm" — not comparable in intensity to pharmacological interventions, but meaningfully pleasant in context. Combination preferences vary: chamomile, lavender, and valerian are popular additions for sleep-oriented preparations; mint or rose are favoured for lighter daytime teas (at lower doses). Quality of source material is cited repeatedly as the single largest variable in outcomes. Improperly stored, old, or adulterated dried flowers consistently produce disappointingly mild results, regardless of preparation method. Storage of Dried Flowers Proper storage has a direct and significant effect on tea quality: Store dried Nymphaea caerulea flowers in an airtight container, kept in a cool, dark, dry location — away from heat sources, direct sunlight, and humidity. Whole flowers retain alkaloid potency considerably longer than ground material. If possible, store flowers whole and grind or crush immediately before preparation. Use within 12 months of harvest/purchase for optimal potency. Older material is not necessarily unsafe, but alkaloid content diminishes meaningfully over time. amama's blue lotus is packaged to support extended shelf life and sourced from suppliers who meet our lab-testing standards for purity and botanical identity. Common Mistakes to Avoid Boiling the water. The single most common preparation error. 100 °C water degrades alkaloids. Target 80–90 °C and keep it there. Steeping for under 10 minutes. Insufficient steeping time means under-extraction, regardless of water temperature. Be patient. Using heavily chlorinated tap water. Chlorine affects flavour and may interact with plant chemistry. Filtered water is always preferable. Combining with alcohol on a first session. Assessing your baseline response to blue lotus requires a clean context. Introduce only one variable at a time. Drinking on a very full stomach without accounting for slower absorption. A full stomach delays absorption — sometimes usefully for a slower, gentler onset, but occasionally leading users to mistakenly consume more before the first dose has taken effect. Safety and Contraindications Do not consume blue lotus tea if you are pregnant or breastfeeding, if you are taking MAOIs (including some antidepressants), prescription sedatives or anxiolytics, blood pressure medication, or if you have a diagnosed heart condition. Nuciferine and apomorphine both exhibit dopaminergic and adrenergic activity that can interact with several categories of psychiatric and cardiovascular medication. If you are uncertain about interactions with your current medication or health status, consult a qualified medical professional before use. Blue lotus tea is an ethnobotanical preparation with a long history of traditional use. It is not a medical treatment and is not intended to diagnose, treat, cure, or prevent any condition. For a detailed breakdown of the pharmacology behind these compounds, see our Nuciferine — Compound Profile. Where to Source Quality Blue Lotus The difference between a well-prepared tea from high-quality dried material and one made from poorly stored or adulterated flowers is, by consistent community report, dramatic. amama curates lab-tested Nymphaea caerulea flowers from ethical suppliers committed to sustainable harvesting and accurate botanical identification. Browse our Blue Lotus collection for whole dried flowers, extracts, and tinctures — all sourced with preparation quality in mind. Related Reading Ultimate Blue Lotus Guide — the full-depth reference for everything Nymphaea caerulea Blue Lotus Effects — what the alkaloids do and how they interact with the body Blue Lotus Preparation Methods — broader overview including smoking, tinctures, and wine infusions Is Blue Lotus Safe? — a grounded look at contraindications, drug interactions, and legal status Last updated: April 2026. Educational content only. Not medical advice. amama products are traditional botanicals, not for medical use. Further Reading The Ultimate Guide to Blue Lotus Blue Lotus Effects Blue Lotus Preparation Is Blue Lotus Safe? Is Blue Lotus Legal? → Nuciferine Compound Profile — chemistry & pharmacology

Learn more

Country/region

The Main Alkaloids of Kratom

Mitragynine

Mitragynine

7-Hydroxymitragynine (7-OH-M)

Speciociliatine, Speciogynine, Paynantheine

Key Studies

Grundmann 2017 — The Largest User Survey

Singh et al. 2014 — Traditional Users in Malaysia

Vicknasingam et al. 2010 — Ketum as Harm Reduction

Prozialeck et al. 2012 — Pharmacological Review

Kruegel & Grundmann 2018 — Modern Receptor Characterization

The 2021 WHO Review: A Significant Outcome

Current Research Landscape

What We Don't Yet Know

Kratom

Back to the Guide

Sources (complete)

Further Reading

Share this article

Related Posts

Country/region

Your cart 0

Order note

Estimate Shipping

Coupon

Search

Your cart